Quercetin for XIAP deficiency in males ages 2 and up
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests if the supplement quercetin can help patients with XIAP deficiency (an immune condition affecting the body's ability to control cell death and inflammation). It is given as a pill or liquid and might reduce inflammation-related symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male
- You must have been diagnosed with XIAP deficiency
- You must be at least 2 years old
- Your IL-18 level must be at least 600 pg/mL (a blood test that shows active inflammation)
- You must be able to take medicine by mouth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a natural supplement called quercetin can help people with dyskeratosis congenita or other telomere biology disorders. These are rare conditions where cells have unusually short telomeres (protective caps on chromosomes), which can affect bone marrow and increase cancer risk.
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
This trial tests an investigational drug called soquelitinib to see if it can shrink enlarged lymph nodes and improve low blood cell counts in people with ALPS-FAS. It may offer a new treatment option for those who have active symptoms.
This trial tests how the body processes quizartinib when the liver is severely impaired. It helps doctors understand if the dose needs to be adjusted for patients with liver issues.
This study tests a gene therapy that delivers a correct copy of the FOXP3 gene to your immune cells (T-cells), turning them into cells that can calm the overactive immune response seen in IPEX syndrome. The goal is to reduce symptoms and the need for lifelong immunosuppressive drugs.
This trial tests a new drug called JANX011 in healthy adults to see if it is safe and well tolerated. It is a first step before testing in patients.
Hear when a new XIAP Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.